Search

Aims: Antimuscarinic drugs are the first‐line choice in the treatment of patients with neurogenic Detrusor Overactivity (nDO). Fesoterodine fumarate is the newest antimuscarinic drug. Limited data are published about the use of fesoterodine fumarate in patients suffering from neurogenic lower urinary tract dysfunction. Our study aims to determine the efficacy of fesoterodine fumarate on patients with nDO due to spinal cord lesion or multiple sclerosis (MS). Methods: This is an open‐label prospective interventional study. Eligible patients were 18–80 years old with SCL or MS and nDO confirmed by a urodynamic study (UDS). At baseline, patients underwent a UDS to confirm nDO. Quality of life (QoL) was assessed by the Short‐Form (SF) Qualiveen questionnaire. Patients received fesoterodine 8 mg/day for 3 months and were re‐evaluated with UDS and SF‐Qualiveen. The primary endpoint was the confirmation of the maximum detrusor pressure (Pdetmax) reduction after treatment. Secondary endpoints were: evaluation of maximum bladder capacity and compliance and QoL effect. Statistical analysis included Wilcoxon‐test using SPSSv26. Results: One hundred and twenty‐four patients completed the study. Ninety‐five of them (76.6%) had SCL, while 29 (23.4%) had MS. Pdetmax, maximum bladder capacity, and compliance had significant reduction after treatment (p <.001) in the whole group and each subgroup. SF‐Qualiveen revealed a significant increase in QoL in each group (p <.001). Conclusions: Fesoterodine fumarate (8 mg) is an efficacious drag in patients with SCL and MS, as it significantly decreases the detrusor pressure, increases the bladder capacity and compliance, and improves the QoL. [ABSTRACT FROM AUTHOR]

Aim To review if the existing data support the new concept that antimuscarinic agents can be used for the treatment of bladder outlet obstruction (BOO) with coexisting overactive bladder (OAB). Method A literature search of Medline publications (up to 2008) on use of antimuscarinic agents for treatment BOO was performed and all data were presented. All relevant data from published studies in congress abstracts were as well included. Results The existing data show that this treatment effectively improves patient quality of life. Concerns about the possibility of urinary retention were shown to be unfounded. It seems that antimuscarinic agents do not affect voiding pressures and the use of antimuscarinic agents for BOO seems safe. Conclusions The combination of an α-blocker and antimuscarinic agent for the treatment of BOO with concomitant OAB seems promising. Neurourol. Urodynam. 29:S46-S50, 2010. © 2010 Wiley-Liss, Inc. [ABSTRACT FROM AUTHOR]

The rare‘burned out’ phenomenon in germ cell tumors is known as the presence of an extragonadal germ cell tumor without traces of neoplasm in the testis. This condition is different and less common from the primary extragonadal germ cell malignancies. These malignancies are treated surgically with or without adjuvant chemotherapy or radiotherapy and their prognosis is better than that of other types of primary extragonadal tumors. [ABSTRACT FROM AUTHOR]